缬沙坦
医学
耐受性
心力衰竭
心肌梗塞
心脏病学
血管紧张素受体
内科学
血管紧张素II
临床试验
糖尿病
安慰剂
药理学
血压
内分泌学
不利影响
替代医学
病理
作者
Nisha Mistry,Arne Westheim,Sverre E. Kjeldsen
标识
DOI:10.1517/14656566.7.5.575
摘要
Valsartan is an angiotensin receptor antagonist that specifically blocks the angiotensin II type 1 receptors. It is an effective and well-tolerated once-daily antihypertensive agent, with a tolerability profile similar to placebo. A recent series of large-scale clinical trials have shown the benefits of valsartan in disease states beyond hypertension. Based on the results of the Val-HeFT (Valsartan in Heart Failure Trial) and VALIANT (Valsartan in Acute Myocardial Infarction Trial) studies, valsartan is indicated for use in patients with heart failure and in patients post-myocardial infarction. Recently, in the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial, valsartan was no more cardioprotective than calcium channel blockers, but was shown to reduce the risk of developing new-onset diabetes in hypertensive patients at high risk of cardiac events compared with calcium antagonist treatment. In diabetic patients with microalbuminuria, valsartan has been shown to have benefits beyond those attributable to blood pressure lowering alone.
科研通智能强力驱动
Strongly Powered by AbleSci AI